Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect
Open Access
- 28 May 2012
- journal article
- Published by SAGE Publications in Lupus
- Vol. 21 (11), 1178-1182
- https://doi.org/10.1177/0961203312450084
Abstract
The influence of antimalarials on lipids in systemic lupus erythematosus (SLE) has been identified in several studies but not in many prospective cohorts. The aim of this study was to longitudinally determine the effect of antimalarials on the lipoprotein profile in SLE. Patients and methods: Fasting total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL) and low-density lipoprotein cholesterol (LDL) plasma levels were determined at entry and after 3 months of hydroxychloroquine (HCQ) treatment in a longitudinal evaluation of 24 patients with SLE. Results: a significant decrease in TC (198 ± 33.7 vs. 183 ± 30.3 mg/dl, p = 0.023) and LDL levels (117 ± 31.3 vs. 101 ± 26.2 mg/dl, p = 0.023) were detected after the 3 months of HCQ therapy. The reduction of 7.6% in TC ( p = 0.055) and 13.7% in LDL levels ( p = 0.036) determined a significant decrease in the frequency of dyslipidemia (26% vs. 12.5%, p = 0.013) after HCQ therapy. Conclusion: This longitudinal study demonstrated the beneficial effect of antimalarials on lipids in SLE since this therapy induced a reduction of atherogenic lipoproteins.Keywords
This publication has 28 references indexed in Scilit:
- Antimalarial treatment may have a time‐dependent effect on lupus survival: Data from a multinational Latin American inception cohortArthritis & Rheumatism, 2010
- Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic reviewAnnals Of The Rheumatic Diseases, 2008
- Hydroxychloroquine: the cornerstone of lupus therapyLupus, 2008
- Systemic lupus erythematosus and “lupus dyslipoproteinemia”Autoimmunity Reviews, 2008
- Prevalence of conventional and lupus‐specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case–control studyArthritis Care & Research, 2006
- The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosusArthritis & Rheumatism, 2006
- Mechanisms of Dyslipoproteinemias in Systemic Lupus ErythematosusJournal of Immunology Research, 2006
- ‘Not only…but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosusRheumatology, 2005
- Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodiesLupus, 1997
- Dyslipoproteinemia in pediatric systemic lupus erythematosusArthritis & Rheumatism, 1988